Use of amyloid-PET to determine cutpoints for CSF markers A multicenter study
| Autor: | Juha O. Rinne, Sanna-Kaisa Herukka, Hilkka Soininen, Charlotte E. Teunissen, Pieter Jelle Visser, Juan Fortea, Ian Law, Alberto Lleó, Marissa D. Zwan, Femke H. Bouwman, Stephen F. Carter, Rafael Blesa, Justyna M.C. Bahl, Agneta Nordberg, Bart N.M. van Berckel, Steen G. Hasselbalch |
|---|---|
| Přispěvatelé: | RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychiatrie & Neuropsychologie, Amsterdam Neuroscience - Neurodegeneration, Neurology, Clinical chemistry, Radiology and nuclear medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Amyloid pathology Pathology Neurology Visual interpretation Concordance Amyloid pet Plaque Amyloid ta3112 Article Cohort Studies 03 medical and health sciences 0302 clinical medicine Alzheimer Disease Internal medicine mental disorders medicine Humans Dementia Cognitive Dysfunction Aged Amyloid beta-Peptides business.industry Correction Middle Aged medicine.disease Peptide Fragments ta3124 030104 developmental biology Multicenter study Positron-Emission Tomography Cohort Female Neurology (clinical) Alzheimer's disease business Psychology Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Neurology, 86(1), 50-58. LIPPINCOTT WILLIAMS & WILKINS NEUROLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Zwan, M D, Rinne, J O, Hasselbalch, S G, Nordberg, A, Lleo, A, Herukka, S-K, Soininen, H, Law, I, Bahl, J M C, Carter, S F, Fortea, J, Blesa, R, Teunissen, C E, Bouwman, F H, van Berckel, B N M & Visser, P J 2016, ' Use of amyloid-PET to determine cutpoints for CSF markers A multicenter study ', Neurology, vol. 86, no. 1, pp. 50-58 . https://doi.org/10.1212/WNL.0000000000002081 Neurology, 86(1), 50-58. Lippincott Williams and Wilkins |
| ISSN: | 1526-632X 0028-3878 |
| DOI: | 10.1212/WNL.0000000000002081 |
| Popis: | Objectives: To define CSF β-amyloid 1–42 (Aβ42) cutpoints to detect cortical amyloid deposition as assessed by 11C-Pittsburgh compound B ([11C]PiB)-PET and to compare these calculated cutpoints with cutpoints currently used in clinical practice.Methods: We included 433 participants (57 controls, 99 with mild cognitive impairment, 195 with Alzheimer disease [AD] dementia, and 82 with non-AD dementia) from 5 European centers. We calculated for each center and for the pooled cohort CSF Aβ42 and Aβ42/tau ratio cutpoints for cortical amyloid deposition based on visual interpretation of [11C]PiB-PET images.Results: Amyloid-PET–based calculated CSF Aβ42 cutpoints ranged from 521 to 616 pg/mL, whereas existing clinical-based cutpoints ranged from 400 to 550 pg/mL. Using the calculated cutpoint from the pooled sample (557 pg/mL), concordance between CSF Aβ42 and amyloid-PET was 84%. Similar concordance was found when using a dichotomized Aβ42/tau ratio. Exploratory analysis showed that participants with a positive amyloid-PET and normal CSF Aβ42 levels had higher CSF tau and phosphorylated tau levels and more often had mild cognitive impairment or AD dementia compared with participants who had negative amyloid-PET and abnormal CSF Aβ42 levels.Conclusions: Amyloid-PET–based CSF Aβ42 cutpoints were higher and tended to reduce intercenter variability compared with clinical-based cutpoints. Discordant participants with normal CSF Aβ42 and a positive amyloid-PET may be more likely to have AD-related amyloid pathology than participants with abnormal CSF Aβ42 and a negative amyloid-PET.Classification of evidence: This study provides Class II evidence that an amyloid-PET–based CSF Aβ42 cutpoint identifies individuals with amyloid deposition with a sensitivity of 87% and specificity of 80%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|